Covance Inc., the Princeton-based provider of drug development services, announced Thursday its boar dhas approved a stock repurchase of up to $100 million of outstanding common stock.
According to the announcement, any purchases under this buyback would be dependent upon business and market conditions and other factors. The stock purchases may be made from time to time and may be made through a variety of methods including open market purchases, privately negotiated transactions, block trades, and 10b5-1 plans.
Stay informed: Subscribe to free NJBIZ newsletters
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy